Clinical trial
10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage…
NCT00004238 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004238 |
|---|---|
| Title | 10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer |
| Official title | A Phase II Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | pralatrexate |
| Start date | Jul 1, 1999 |
| Primary completion | Jun 1, 2002 |
| Completion | Jun 1, 2002 |
| First posted | Apr 12, 2004 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: